Inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) is caused by mutations in Valosin-containing protein (VCP), a hexameric AAA ATPase that participates in a variety of cellular processes such as protein degradation, organelle biogenesis, and cell-cycle regulation. To understand how VCP mutations cause IBMPFD, we have established a Drosophila model by overexpressing TER94 (the sole Drosophila VCP ortholog) carrying mutations analogous to those implicated in IBMPFD. Expression of these TER94 mutants in muscle and nervous systems causes tissue degeneration, recapitulating the pathogenic phenotypes in IBMPFD patients. TER94-induced neurodegenerative defects are enhanced by elevated expression of wild-type TER94, suggesting that the pathogenic alleles are dominant active mutations. This conclusion is further supported by the observation that TER94-induced neurodegenerative defects require the formation of hexamer complex, a prerequisite for a functional AAA ATPase. Surprisingly, while disruptions of the ubiquitin-proteasome system (UPS) and the ER–associated degradation (ERAD) have been implicated as causes for VCP–induced tissue degeneration, these processes are not significantly affected in our fly model. Instead, the neurodegenerative defect of TER94 mutants seems sensitive to the level of cellular ATP. We show that increasing cellular ATP by independent mechanisms could suppress the phenotypes of TER94 mutants. Conversely, decreasing cellular ATP would enhance the TER94 mutant phenotypes. Taken together, our analyses have defined the nature of IBMPFD–causing VCP mutations and made an unexpected link between cellular ATP level and IBMPFD pathogenesis. Inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) is a progressive autosomal dominant disease, characterized by the adult onset of muscle degeneration, abnormal bone metabolism, and drastic behavior changes. IBMPFD is caused by specific mutations in the highly conserved VCP gene, an ATPase known to participate in numerous cellular functions. Because of its diverse functions, it has been difficult to decipher how VCP mutations cause this debilitating disorder. To understand how these specific mutations in VCP lead to IBMPFD, we have developed a Drosophila IBMPFD model by introducing analogous mutations in TER94, the fly VCP homolog. We show that TER94 carrying these specific mutations can disrupt the fly muscle and nervous systems, similar to the symptoms of IBMPFD in humans. These phenotypic similarities suggest that information gained from our analysis of TER94 will enhance our understanding of how VCP mutations cause IBMPFD. By subjecting our fly IBMPFD model to various physiological and genetic manipulations, we have uncovered a novel link between the disease progression and cellular ATP level. Thus, in addition to establishing a fly model for further analysis of this disease, our finding should suggest new therapeutic strategies for IBMPFD.